FATE News and Press, Fate Therapeutics Inc. From 07/19/22

The recent stock rally has made some crowded shorts more squeezable, according to S3 Partners' Ihor Dusaniswky. Dusaniswky created a ranking of the most crowded shorts based on factors like total short dollars at risk, short interest as a true percentage of a company's tradable floa...

ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total return of 69.6%, an...

Fate Therapeutics ( NASDAQ: FATE ) has appointed Brian Powl as its new chief commercial officer . He was most recently SVP, commercial development & marketing at MEI Pharma ( MEIP ). Before then, he was VP, global commercial CAR T lead at Celgene Corp....

SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr....

Fate Therapeutics (NASDAQ:FATE) said it expanded its cancer immunotherapy collaboration with Japan's Ono Pharmaceutical (OTCPK:OPHLY) (OTC:OPHLF) to include the development of chimeric antigen receptor (CAR) NK cell candidates. In addition, under the expansion, Ono will contribute novel bindi...

ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partnership Enables Development of both CAR NK and CAR T-cell Collaboration Candidates for Solid Tumors SAN DIEGO, June 28, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, In...

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the ...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total return of 73.6%, an...

Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsed/refractory diffuse large B-cell lymphoma. If all goes well with FDA meeting for FT516, then a pivotal study should begin in the second half of 2022. FT516 is being ...